Bispecific antibody · Immune activation, directed at programmed death-ligand 1 (CD274) and gamma-delta T-cell receptor Vdelta1 segment (TRDV1) · developed by TAKEDA PHARMACEUTICAL CO
TAK-505 is a bispecific T-cell engager that binds PD-L1 on tumor cells and the Vdelta1 segment of the gamma-delta T-cell receptor on gamma-delta T-cells. By bringing these cells together, it induces the cytotoxic activity of Vdelta1 gamma-delta T-cells against tumor cells. It is being studied in malignant solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07436728 | Phase 1/2 | Malignant Solid Tumors | Recruiting | TAK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Malignant Solid Tumors
Updated Nov 8, 2026. Something wrong or missing? Report it on the TAK page.
See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TAK catalysts and pipeline →